Each dot is a country. Horizontal axis is health spending per person. Vertical axis is the outcome you choose. If money bought health in a straight line, the dots would form one. They do not, and one country sits conspicuously off the pattern.
Medical bankruptcy is the one measure where the comparison is not a matter of degree.
In twenty-six of these twenty-seven countries, being ill cannot bankrupt you, because catastrophic costs are structurally capped. The mechanism does not exist. In the United States it does, and the debate is only about size. Research led by Himmelstein finds roughly two thirds of people filing for bankruptcy cite medical bills or illness as a contributor. Dobkin and colleagues, isolating the causal effect of a single hospital admission, put the directly attributable share nearer 4 percent. Both figures are defensible; they measure different things. What neither side disputes is that the category exists in America and effectively nowhere else in the developed world.
Every system, and what it feels like to use
Sorted by spending. The rating bars are editorial judgments informed by Commonwealth Fund and OECD access data, not measurements. Five pips is best. Waits and quality are not the same axis: a system can deliver excellent medicine slowly, or mediocre medicine quickly.
On the ratings. Spending, infant mortality, and life expectancy are measured data and are cited below. The wait-time and quality pips are not. They are judgments drawn from Commonwealth Fund survey work, OECD access statistics, and published national waiting-list data, compressed onto a five-point scale so systems can be compared at a glance. They will be wrong at the margins and are offered to be argued with. Wait times in particular vary enormously within a country by region and procedure, and a national average conceals that.
What the scatter shows. Among developed nations, above roughly four thousand dollars per person, additional health spending buys very little additional life. Japan spends $5,365 and reaches 84.7 years with the lowest infant mortality in the world. The United States spends $13,473, two and a half times as much, and reaches 79.3 years with the highest infant mortality in this group. Greece spends a quarter of what America spends and outlives it by two and a half years. The curve flattens hard, and the United States is not on it at all.
The scarcinality reading. This is the framework's clearest worked example, and the companion dispatch The Counterfeit Shortage of Care develops it in full. The United States is told it cannot afford to cover everyone. But it already spends more per person than any country that does cover everyone. The doctors exist, the hospitals exist, the drugs exist, and the money is already being spent. Nothing real has run out. What is scarce is not medicine but the monetary claim that would move it to the people who need it, and that scarcity is manufactured one level up, in how the claim is ordered and who is permitted to hold it. Every other country on this chart made a different ordering decision and got more health for less money.
And the honest counterweight. Universal systems ration too. They ration by time rather than by price, and the Canadian and British queues are real, not propaganda: Canada's median wait from referral to treatment reached 30 weeks in 2024, the longest in that survey's thirty-year history. A system that makes care free at the point of use and then makes you wait eleven months for a hip has not abolished scarcity, it has relocated it. The framework's point is not that queues are costless. It is that a queue and a bankruptcy are two different ways of rationing the same abundant thing, and only one of them takes the house.
Sources: health spending per capita, World Bank and OECD via Our World in Data, 2023 to 2024 depending on country. Infant mortality, World Bank, 2023. Life expectancy at birth, Our World in Data, 2023. Wait time and quality ratings are editorial, informed by Commonwealth Fund Mirror Mirror 2024 and OECD Health at a Glance. Bankruptcy discussion draws on Himmelstein et al. and Dobkin et al.